Stryker (NYSE:SYK) Trading Down 4.9% – What’s Next?

Shares of Stryker Corporation (NYSE:SYK) traded down 4.9% during mid-day trading on Tuesday . The company traded as low as $312.45 and last traded at $314.2130. Approximately 601,073 shares were traded during mid-day trading, a decline of 74% from the average session volume of 2,337,239 shares. The stock had previously closed at $330.52.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on SYK shares. Needham & Company LLC lowered their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. BTIG Research decreased their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. UBS Group dropped their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Evercore set a $355.00 price objective on shares of Stryker in a report on Friday, May 1st. Finally, Truist Financial reissued a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Stock Performance

The company has a market capitalization of $119.96 billion, a P/E ratio of 36.19, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78. The business has a 50 day moving average of $310.95 and a 200 day moving average of $339.70. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same period last year, the company earned $2.84 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter valued at $26,000. Sankala Group LLC purchased a new position in shares of Stryker during the 4th quarter worth about $26,000. United Financial Planning Group LLC bought a new position in Stryker during the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker in the 4th quarter worth about $27,000. Finally, DJE Kapital AG bought a new stake in Stryker in the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.